TERAPEUTISK AKTIV, SUBSTITUERET BENZIMIDAZOLDERIVAT OG FYSIOLOGISK ACCEPTABLE SALTE HERAF SAMT FREMGANGSMAADE TIL FREMSTILLING AF SAMME

摘要

Previously unknown 5-chloro-2-[[(3,4-dimethoxy-2- pyridinyl)methyl]sulphinyl]-1H-benzimidazole, and physiologically acceptable salts thereof as well as pharmaceutical preparations which comprise the compound as the active constituent, have a gastric acid secretion- inhibiting effect on mammals, including humans. The patent also describes intermediate compounds and a process for preparing the compound and the use of the compound as a medicament.